Want to see PEPG full AI Analyst Report?
PEPG Stock Chart & Stats
$1.93
-$0.17(-8.10%)
At close: 4:00 PM EDT
$1.93
-$0.17(-8.10%)
Day’s Range― - ―
52-Week Range$1.01 - $7.80
Previous CloseN/A
Volume735.00K
Average Volume (3M)6.68M
Market Cap
$121.74M
Enterprise Value$6.55
Total Cash (Recent Filing)$132.30M
Total Debt (Recent Filing)$16.56M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding69,169,210
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.86
Price to Sales (P/S)0.00
P/FCF Ratio-3.36
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside366.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary EDO Delivery PlatformPepGen's proprietary Enhanced Delivery Oligonucleotide (EDO) platform addresses a durable, structural barrier in oligonucleotide therapeutics: tissue delivery (including muscle). A platform that meaningfully improves delivery can provide sustained competitive advantage across multiple neuromuscular indications and support scalable pipeline expansion beyond a single program.
Clinical Progress And Regulatory DesignationsEmerging safety and efficacy signals plus regulatory designations in major jurisdictions reduce development and regulatory risk on a structural level. Global enrollment and expected higher-dose cohorts between 2026–2027 imply a persistent development pathway, improving the odds of accelerated review, partnering, or conditional approvals that materially alter long-term commercial prospects.
Low Leverage And Equity CushionA low debt-to-equity ratio and meaningful recorded equity reduce near-term refinancing pressure and bankruptcy risk versus highly leveraged peers. This conservative capital structure gives management more strategic optionality (partnering, staged spend) and more runway to advance programs before reliance on costly debt financing becomes necessary.
Bears Say
No Revenue / Pre-commercial ProfileAs a development-stage biotech with no product revenue, PepGen lacks internally generated, recurring cash flow to fund operations. This structural reliance on external capital increases execution risk, reduces margin visibility, and makes long-term sustainability contingent on successful trials, partnerships, or repeat financings rather than business-generated cash.
High And Persistent Cash BurnConsistently large negative operating and free cash flow (~-$77M TTM) represents a durable drain on resources. High burn necessitates recurring capital raises or partner funding; over multiple quarters this depletes shareholder equity, forces dilution, and limits ability to self-fund later-stage trials or commercial launch preparations without material external support.
Erosion Of Equity And Dilution RiskThe steady decline in equity signals persistent losses being financed by capital markets. Structurally, repeated dilution to cover development costs can erode existing shareholders' stakes, constrain management's freedom to pursue costly trials, and raise the hurdle for accretive partnerships or M&A absent demonstrable clinical de-risking.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $1.01 and its highest was $7.80 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $121.74M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on May 12, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.293 by $0.033.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.28.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 69,169,210 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.293. Following the earnings report the stock price went up 5.952%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PepGen Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (366.32% Upside)
$9.00 (366.32% Upside)
Hedge Fund Trend
Decreased
By 865.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.69%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc. (PEPG) is a clinical-stage biotechnology company developing oligonucleotide-based therapeutics using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, with an initial focus on neuromuscular and other severe genetic diseases. The company’s pipeline includes EDO-based candidates designed to improve delivery of nucleic acid therapies to target tissues (including muscle), and it advances these programs through preclinical and clinical development rather than providing commercial products or services.
PEPG Stock 12 Month Forecast
Average Price Target
$9.00
▲(366.32% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
37.05% Insiders
3.70% Mutual Funds
0.06% Other Institutional Investors
55.18% Public Companies and
Individual Investors